Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon

Immunobiology

Volumn 218, Issue 5, 2013, Pages 725-732

  Shimizu, Taro ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anti PEG IgM; Innate immunity; Marzinal zone B cells; PEGylated liposome

Indexed keywords

CHOLESTEROL; CYCLOPHOSPHAMIDE; GLYCEROPHOSPHOETHANOLAMINE; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; PEGYLATED LIPOSOME; POLYETHYLENE GLYCOL IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ACCELERATED BLOOD CLEARANCE PHENOMENON; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL POPULATION; CONTROLLED STUDY; FOLLICLE B CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; INTERNALIZATION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SPLENIC MARGINAL ZONE B CELL;

ANIMALS; ANTIGENS, T-INDEPENDENT; B-LYMPHOCYTES; BIOLOGICAL TRANSPORT; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; METABOLIC CLEARANCE RATE; MOLECULAR MIMICRY; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SPLEEN;

EID: 84875653451     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.08.274     Document Type: Article

References (46)

1. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
2. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 1959, 234:469-471.
3. Carrasco Y.R., Batista F.D. B cell recognition of membrane-bound antigen: an exquisite way of sensing ligands. Curr. Opin. Immunol. 2006, 18:286-291.
4. Cinamon G., Zachariah M.A., Lam O.M., Foss F.W., Cyster J.G. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat. Immunol. 2008, 9:54-62.
5. Cyster J.G. B cells on the front line. Nat. Immunol. 2000, 1:9-10.
6. Dammers P.M., Visser A., Popa E.R., Nieuwenhuis P., Kroese F.G. Most marginal zone B cells in rat express germline encoded Ig VH genes and are ligand selected. J. Immunol. 2000, 165:6156-6169.
7. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., Corstens F.H., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
8. Dintzis R.Z., Okajima M., Middleton M.H., Greene G., Dintzis H.M. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J. Immunol. 1989, 143:1239-1244.
9. Ferguson A.R., Youd M.E., Corley R.B. Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells. Int. Immunol. 2004, 16:1411-1422.
10. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 2006, 8:R12.
11. Gauld S.B., Benschop R.J., Merrell K.T., Cambier J.C. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 2005, 6:1160-1167.
12. Harms G., Hardonk M.J., Timens W. In vitro complement-dependent binding and in vivo kinetics of pneumococcal polysaccharide TI-2 antigens in the rat spleen marginal zone and follicle. Infect. Immun. 1996, 64:4220-4225.
13. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Ishida T., Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011, 3:1-11.
14. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
15. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317.
16. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250.
17. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.
18. Ishida T., Maeda R., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 2003, 88:35-42.
19. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 2007, 122:349-355.
20. Ishihara T., Takeda M., Sakamoto H., Kimoto A., Kobayashi C., Takasaki N., Yuki K., Tanaka K., Takenaga M., Igarashi R., Maeda T., Yamakawa N., Okamoto Y., Otsuka M., Ishida T., Kiwada H., Mizushima Y., Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 2009, 26:2270-2279.
21. Janeway C., Travers P., Walport M., Shlomchik M. Immuno Biology: the Immune System in Health and Disease 2005, Garland Science, New York and London. 6th ed.
22. Kaminskas L.M., McLeod V.M., Porter C.J., Boyd B.J. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci. 2011, 100:5069-5077.
23. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
24. Koide H., Asai T., Hatanaka K., Akai S., Ishii T., Kenjo E., Ishida T., Kiwada H., Tsukada H., Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm. 2010, 392:218-223.
25. Kraal G. Antigens take the shuttle. Nat. Immunol. 2008, 9:11-12.
26. Kraal G. Cells in the marginal zone of the spleen. Int. Rev. Cytol. 1992, 132:31-74.
27. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991, 1070:187-192.
28. Laverman P., Brouwers A.H., Dams E.T., Oyen W.J., Storm G., van Rooijen N., Corstens F.H., Boerman O.C. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J. Pharmacol. Exp. Ther. 2000, 293:996-1001.
29. Laverman P., Carstens M.G., Boerman O.C., Dams E.T., Oyen W.J., van Rooijen N., Corstens F.H., Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 2001, 298:607-612.
30. Lopes-Carvalho T., Foote J., Kearney J.F. Marginal zone B cells in lymphocyte activation and regulation. Curr. Opin. Immunol. 2005, 17:244-250.
31. MacLennan I.C. B cells: the follicular dimension of the marginal zone. Immunol. Cell Biol. 2008, 86:219-220.
32. MacLennan I.C., Liu Y.J. Marginal zone B cells respond both to polysaccharide antigens and protein antigens. Res. Immunol. 1991, 142:346-351.
33. Martin F., Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 2001, 13:195-201.
34. Martin F., Oliver A.M., Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001, 14:617-629.
35. Mond J.J., Lees A., Snapper C.M. T cell-independent antigens type 2. Annu. Rev. Immunol. 1995, 13:655-692.
36. Morisaki I., Eldridge J.H., Michalek S.M., Hamada S., McGhee J.R. Immunoregulation in the rat: requirements for in vitro B cell responses to classical TI-1 and TI-2 antigens. J. Immunol. 1983, 131:1131-1137.
37. Mosier D.M.S.B. Thymus-independent antigens: complexity of B lymphocyte activatin revealed. Immunol. Today 1982, 3:217-222.
38. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:11460-11464.
39. Peset Llopis M.J., Harms G., Hardonk M.J., Timens W. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J. Allergy Clin. Immunol. 1996, 97:1015-1024.
40. Richter A.W., Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 1983, 70:124-131.
41. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
42. Szomolanyi-Tsuda E., Brien J.D., Dorgan J.E., Garcea R.L., Woodland R.T., Welsh R.M. Antiviral T-cell-independent type 2 antibody responses induced in vivo in the absence of T and NK cells. Virology 2001, 280:160-168.
43. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
44. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 2007, 119:236-244.
45. Zandvoort A., Lodewijk M.E., Klok P.A., Dammers P.M., Kroese F.G., Timens W. Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity. Clin. Exp. Immunol. 2001, 124:172-179.
46. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 2002, 130:4-11.